United States - English - NLM (National Library of Medicine)

raritan pharmaceuticals - dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots) - cough suppressant

United States - English - NLM (National Library of Medicine)

raritan pharmaceuticals - guaifenesin (unii: 495w7451vq) (guaifenesin - unii:495w7451vq), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - expectorant nasal decongestant these could be signs of a serious illness.

United States - English - NLM (National Library of Medicine)

raritan pharmaceuticals - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots) - pain reliever/fever reducer cough suppressant

United States - English - NLM (National Library of Medicine)

army and air force exchange service - sennosides (unii: 3fyp5m0ijx) (sennosides - unii:3fyp5m0ijx) - laxative uses do not use stop use and ask a doctor if you have rectal bleeding or fail to have a bowel movement after use of a laxative. these may indicate a serious condition. important : keep this carton for future reference on full labeling. *this product is not manufactured or distributed by avrio health l.p., owner of the registered trademark senokot® “satisfaction guaranteed or your money back” manufactured for your military exchanges by: raritan pharmaceuticals inc., 8 joanna court, east brunswick, nj 08816

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - griseofulvin 125 mg in 5 ml - major indications for griseofulvin oral suspension are: tinea capitis (ringworm of the scalp) tinea corporis (ringworm of the body) tinea pedis (athlete's foot) tinea unguium (onychomycosis; ringworm of the nails) tinea cruris (ringworm of the thigh) tinea barbae (barber's itch) griseofulvin oral suspension inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as: trichophyton rubrum trichophyton tonsurans trichophyton mentagrophytes trichophyton interdigitalis trichophyton verrucosum trichophyton sulphureum trichophyton schoenleini microsporum audouini microsporum canis microsporum gypseum epidermophyton floccosum trichophyton megnini trichophyton gallinae trichophyton crateriform note: prior to therapy, the type of fungi responsible for the infection should be identified. the use of the drug is not justified in minor or trivial infections which will respond to topical anti-fungal agents alone. it is not effective in: bacterial infection

United States - English - NLM (National Library of Medicine)

rebel distributors corp - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol (unii: h8a007m585) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - 1 indications and usage nucynta® (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. 4 contraindications 4.1 impaired pulmonary function like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . 4.2 paralytic ileus like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. 4.3 monoamine oxidase inhibitors nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which ma

United States - English - NLM (National Library of Medicine)

stat rx usa llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol hydrochloride 75 mg - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - pentosan polysulfate sodium (unii: 914032762y) (pentosan polysulfate - unii:f59p8b75r4) - pentosan polysulfate sodium 100 mg - elmiron® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. elmiron® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.